Showing 354 results
January 2021
December 2020
-
Story Hope
Working Together at Novartis to Fight COVID-19 and Help People in Need -
Media ReleaseNovartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEFThe Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval…
-
Media ReleaseNovartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancerMONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1 Kisqali plus endocrine therapy had a median OS of nearly five years (58.7…
-
Media ReleaseNovartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trialAt 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase…
-
Media ReleaseNovartis and Amgen partner with Karamo Brown to support and empower people living with migraineThe Know Migraine Mission initiative seeks to challenge misconceptions and start new conversations about migraine Karamo Brown to connect directly with people affected by migraine to share…
-
Media ReleaseNovartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polypsXolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation Xolair is now FDA-approved across three diseases and in…
November 2020
-
Media ReleaseNew data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseasesPivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIs ELARA results for Kymriah® in relapsed or…
-
Media ReleaseNew Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and genderPooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult…
-
Story Medicines
Novartis looks to the brightest academic minds to reimagine metastatic breast cancer treatment -
Media ReleaseNovartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind studySignificant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx® at Week 12 vs. placebo, with improvements as early as Week 11 ULTIMATE is the first ever Phase IIIb…